This study presents BI-RADS 3–5 microcalcifications can be conveniently used to facilitate the preoperative individualized prediction of HER2 and Luminal A molecular subtype in patients with infiltrating ductal carcinoma. This evidence concerns the gene ERBB2 and invasive ductal breast carcinoma.